Human interferon-beta formulations
AssigneeSchering Corporation
InventorsMichael McCaman, Susanne Ottoboni, Erno Pungor
Life of this patent
Estimating the term…
Abstract
The invention provides a stable pharmaceutical composition containing biologically active human interferon-β (IFN-β), preferably IFN β1b produced in a bacterial host, dissolved in an aqueous-based solution containing a glycine buffer at a pH of about 2.0 to about 4.0. The invention of also provides stable IFN-β lyophilizates prepared from biologically active IFN-β, dissolved in an aqueous-based solution containing a glycine buffer at a pH of about 2.0 to about 4.0.
Claims35
An pharmaceutical composition consisting essentially of biologically active IFN-β1b and of glycine buffer that achieves a pH of about 2 to about 4.
A composition comprising about 5 mg/ml biologically active IFN β-1b in glycine buffer at about pH 3.0.
Dependencies are inferred from the claim text.